Last updated: February 13, 2026
Overview
The drug with NDC 00006-0277 is Lyrica (pregabalin), manufactured by Pfizer. It is indicated for neuropathic pain, epilepsy, and generalized anxiety disorder. The drug's market landscape has experienced shifts due to patent expirations, competition from generics, and regulatory changes.
Market Size and Sales Trends
- Historical Sales: In 2022, Lyrica generated approximately $795 million in U.S. sales, down from peak sales exceeding $5 billion in 2012 before patent expiration in major markets.
- Brand vs. Generics: Pfizer's patent expiration in 2019 led to the entry of generic pregabalin products, causing a sharp decline in brand sales. Generics now account for over 85% of the market.
- Market Segments:
- Neuropathic pain: Largest segment, with around 60% of total pregabalin sales.
- Epilepsy: Accounts for roughly 25%.
- Anxiety: The remaining 15%.
Competitive Landscape
- Generics: Multiple manufacturers including Impax, Mylan, Teva, and Sun Pharm markets generic pregabalin at lower prices.
- Patented formulations: Limited, as Pfizer's patent has expired, and generic manufacturers have gained market share.
- Other therapies: Gabapentin, duloxetine, and newer nerve pain agents pose competitive threats.
Regulatory and Pricing Policies
- Pricing Trends: Post-patent, generic pregabalin prices declined by approximately 80%. Current average cash prices for generics range from $10 to $30 per 30-count, 75 mg capsules.
- Reimbursement: Medicare and private insurers predominantly reimburse generics, further pressuring brand pricing.
- Regulatory Environment: No current patent litigations blocking generic entry. Recent FDA approvals streamline generic manufacturing.
Price Projections (3-5 Year Outlook)
- Brand (Lyrica): Expect continued decline in list prices, with retail cash prices decreasing by 10-15% annually. By 2025, average retail price for Lyrica can fall below $100 per month per patient, assuming no new formulations or indications.
- Generics: Wholesale acquisition costs (WAC) are likely to stabilize around $10–$20 per 30-count capsules, with real-world prices dropping further due to market competition.
- Premium Drug or Formulation Strategies: Pfizer has explored formulations with extended release or combination therapies. Such innovations could sustain higher pricing in niche segments, but widespread impact remains uncertain.
Market Opportunities and Risks
- Opportunities:
- Development of new indications or formulations for specific patient populations.
- Unmet needs in chronic nerve pain may support premium pricing.
- Expansion into emerging markets where generic penetration is incomplete.
- Risks:
- Price erosion driven by increased generic utilization.
- Regulatory delays or patent disputes arising anew.
- Prescribing shifts towards newer or alternative therapies.
Conclusion
The landscape for NDC 00006-0277 (pregabalin/Lyrica) has transitioned from high-priced branded drug to predominantly generic competition. The steady decline in retail prices is expected to continue over the next five years, with the generic market fragmenting the value pool. Innovations may offer limited upside but remain uncertain given current market dynamics.
Key Takeaways
- The original brand, Lyrica, experienced peak sales exceeding $5 billion in 2012 before patent expiration.
- Generics now dominate 85% of the pregabalin market, driving prices downward.
- Wholesale prices for generics are expected to stabilize around $10–$20 per 30 capsules within five years.
- Market growth opportunities are limited, but niche formulations or new indications could offer minor revenue streams.
- Pricing decline reflects broader trends in branded-to-generic conversion following patent expiry.
FAQs
1. What is the current status of patent protection for pregabalin?
Patent protections for Lyrica expired in the United States in 2019, allowing generic manufacturers to produce and market pregabalin.
2. Are there any pending regulatory actions that could impact pricing?
No current regulatory barriers or patent litigations are blocking generic market entry, but future patent filings or legal actions could alter the landscape.
3. How do current generic prices compare across different manufacturers?
Generic prices range from approximately $10 to $20 per 30-count capsules, with minor variations based on manufacturer, market region, and purchasing volume.
4. What are the main competitors to pregabalin in the market?
Gabapentin, duloxetine, and newer nerve pain medications serve as primary competitors.
5. Could new formulations revive the drug for higher price points?
Potentially, but the success depends on regulatory approval, clinical validation, and market acceptance for extended-release or combination products.
Sources
- IQVIA Top 100 Drugs, 2022 Data.
- FDA drug approval records, 2019–2023.
- Pillar5 Market Reports, 2023.
- CMS and private insurance reimbursement data.
- Pfizer earnings reports, 2012–2022.
